25-49 year olds: Malignant neoplasms (tumors, cancers and lymphomas) (C00-D48) 1/x
25-49 -vuotiaat: syövät, kasvaimet ja lymfoomat (C00-D48) 2/x
These are the 20 cancers, tumors, and lymphomas experiencing the fastest y/y patient growth in 2023. Together, they account for 12 percent of the total patient count. There is a significant representation of cancers and tumors affecting the female genital region. 3/x
Tässä ovat 20 nopeimmin vuosittain kasvavaa syöpää, kasvainta ja lymfoomaa vuonna 2023. Ne muodostavat noin 12 prosenttia kokonaispotilasmäärästä. Naisten sukuelinten alueen syövillä ja kasvaimilla on merkittävä edustus. 4/x
The 20 fastest growing cancers, tumors and lymphomas affect 0.1 percent of 25-49 year population. Weighted average y/y patient growth rate in 2023 is 56 percent per year (= 9 times in five years). 5/x
20 nopeimmin kasvavaa syöpää, kasvainta ja lymfoomaa vaikuttavat 0.1 prosenttiin 25–49-vuotiaiden väestöstä. Painotettu keskimääräinen v/v potilasmäärän kasvuvauhti vuonna 2023 on 56 prosenttia vuodessa (= 9-kertaistuu viidessä vuodessa). 6/x
Next, let us review cancers, tumor and lymphomas in the female genital areas. In public outpatient healthcare, most of them have started to show significant y/y patient growth in 2023 (total y/y patient growth rate is 30 percent). 7/x
Katsotaan seuraavaksi naisen sukupuolielinten alueiden syöpiä ja kasvaimia. Julkisessa avoterveydenhuollossa useimmat niistä ovat alkaneet osoittaa merkittävää v/v potilasmäärän kasvua vuonna 2023. Keskimääräinen kasvuvauhti vuonna 2023 on 30 prosenttia. 8/x
Cancers and tumors in female genital areas affect roughly 0.24 percent of 25-49 year old female population. The figure is growing 30 percent annually (= 10 times in ln(10)/ln(1.3) = 9 years). These figures include public outpatient healthcare only. 9/x
Naisten sukuelinten alueen syövät ja kasvaimet vaikuttavat noin 0.24 prosenttiin 25–49-vuotiaasta naisväestöstä. Luku kasvaa 30 prosenttia vuosittain (= 10-kertaistuu ln(10)/ln(1.3) = 9 vuodessa). Yksityinen ja työterveyshoito puuttuvat näistä luvuista. 10/x
In total outpatient healthcare, cancers and tumors in the female genital area affect roughly 0.459x2 = 0.92 percent of 25-49 year old females, and the figure is growing 28.5 percent annually (10 times in ln(10)/ln(1.285) = 9 years). 11/x
Koko avoterveydenhuollossa naisten sukuelinten alueen syövät ja kasvaimet vaikuttavat noin 0.459x2 = 0.92 prosenttiin 25–49-vuotiaista naisista, ja määrä kasvaa 28.5 prosenttia vuosittain (eli 10-kertaistuu ln(10)/ln(1.285) = 9 vuodessa). 12/x
• • •
Missing some Tweet in this thread? You can try to
force a refresh
After more than five years of silence, mainstream media has begun to acknowledge that C19 can harm T cells, and to discuss the consequences that follow. @fitterhappierAJ was one of the first, if not the first, to talk about this. 1/x
Dr. Leonardi has provided a significant amount of direction for me. In particular, he has been interviewed in some excellent articles that have withstood the test of time. Here is one of them. 2/x
We have seen it all.
- in 2020, they said that our health systems are so robust that this disease wouldn't come here
- then they wanted them infected. C19 was de facto allowed to spread in schools. Only a small fraction of <12 year olds received ... 3/x
Something is causing injuries among young children. 1/x
Something changed in 2022. Before that, the numbers were generally falling. Wonder what it could be. 2/x
After 2022, 1-6 year olds have overtaken a total of three other age groups (50-64, 15-24 and 65-74 year olds), and are now clearly above the total population average. All injuries (S00-S99). 3/x
Between 2020 and 2025e, the number of patients with developmental delay or disorder diagnoses grew at an average annual rate of 21.6% (10x in 11.8 years). The fastest patient growth was seen in pervasive developmental disorders, incl. autism and Asperger syndrome (F84). 2/x
Among total population, number of patients with developmental delay or disorder diagnoses is up 2.6 times since 2020. All disorders are showing continued significant patient growth. 3/x
Finland's epidemic 23 Dec 2025: amount of virus in wastewater appears to have risen above the first Omicron wave. Post-Omicron baseline is permanently higher than pre-Omicron; repeated waves are showing no diminishing. 1/x
Post-Omicron baseline is permanently higher than pre-Omicron
- before late 2021, levels were mostly 10³–10⁴.
- from 2022 onward, even troughs sit around 10⁵, or 10-100x higher
- C19 has become endemic
- constant background transmission, even outside waves 2/x
Repeated large waves in 2023–2024, not diminishing. Notable peaks:
- Apr 2023
- Nov 2023 (highest for the entire pandemic)
- Dec 2024
These peaks are:
- comparable to or higher than Omicron 2022
- evidence against a simple “each wave gets smaller” narrative 3/x
Congenital malformations, deformations and chromosomal abnormalities. For 1-6 year olds,
- the condition showing largest increase since 2022 is Down's syndrome (Q90)
- the condition showing fastest growth since 2022 is Congenital malformations of great arteries (Q25) 1/x
1-6 year olds / chromosomal abnormalities (Q90-Q99).
- Down's syndrome (Q90): average patient growth (2022-2025e) 14% per year = 10x in 18 years)
- fastest growing condition: other sex chromosome abnormalities, male phenotype (Q98), up 150% in 2025e 2/x
<1 year olds / chromosomal abnormalities (Q90-Q99):
- Down's syndrome (Q90) is the most frequent diagnosis 3/x
Intellectual disabilities (F70-F79): <1 year olds are leading in terms of y/y growth. Ten percent of <1 year olds will have an intellectual disability diagnosis in 14 year's time (2039), if current growth rates continue. 1/x
The rise in intellectual disability among <1 year olds also shows in number of diagnoses: up roughly 11 times in 4 years. Also note the rise among 1-6 year olds. 2/x
7-14 and 15-24 year olds are showing the highest levels of intellectual disability. If current growth rates continue, 5 percent of 7-14 and 15-24 year olds will have an intellectual disability diagnosis by 2048 (24 years from now). 3/x